

Peter Lawrence, MD
VLFDC Director
University of California,
Los Angeles

Karen Woo, MD
Associate Director
University of California,
Los Angeles

Jonathan Bath, MD
Associate Director
University of Missouri

Nakeisha Favors, MPH
Program Coordinator
University of California,
Los Angeles

Steering Committee

Chris Abularrage, MD
John Hopkins School of
Medicine

Christian Behrendt, MD
University of Hamburg

Dawn Coleman, MD
University of Michigan

Randall DeMartino, MD
Mayo Clinic, Rochester

Luc Dubois, MD
University of Western
Ontario

Naoki Fujimura, MD
Keio University School of
Medicine

Nasim Hedayati, MD
University of California,
Davis

Daniella Kadian-Dodov,
MD
Icahn School of Medicine
at Mount Sinai

Alberto Munoz, MD
National University of
Colombia

Marc Passman, MD
University of Alabama at
Birmingham School of
Medicine

Marc Schermerhorn, MD
Harvard Medical School

Sherene Shalhub, MD
University of Washington
School of Medicine

Courtney Warner, MD
Albany Medical College

Manar Khashram, MBChB
University of Auckland

DATE

Dear Colleague,

On behalf of the Vascular Low Frequency Disease Consortium (VLFDC), we would like to invite you to become a co-investigator in a multi-institutional research project on _(disease process)_.

The VLFDC is a collaborative effort among investigators from institutions across the US and the world to study management and outcomes of uncommon vascular conditions. The collaborative effort allows for a large enough sample size to provide sufficient power for drawing meaningful conclusions that would otherwise be difficult to make with the small numbers of patients treated at any individual institution. To date, the VLFDC has involved over 70 institutions and 135 investigators in the United States and overseas, and each completed project has resulted in presentations at national conferences and publications in high impact, peer-reviewed journals. We will be investigating _____(management/therapies for disease process)_____.

With your help, we hope to accumulate data on approximately _(number)_ patients with _(disease process)_ over a _(number)_ year period (date range). We estimate that it will take _(number)_ minutes to complete data submission for each patient. The study will be submitted to the ___ Meeting. To meet this deadline, we would like to begin collecting data ASAP and complete the collection by _(one month prior to abstract deadline)_.

All co-investigators and/or contributors of data who 1) make substantial contributions to the conception or design of the work; the acquisition, analysis, or interpretation of data for the work; 2) draft the work or revise it critically for important intellectual content; and 3) provide final approval of the version to be published; will be included as co-authors in the publication.

Please do not hesitate to contact us with any questions. We look forward to hearing from you.

Sincerely,

_____, MD, Principal Investigator
PI EMAIL ADDRESS